1. Home
  2. THAR vs SNOA Comparison

THAR vs SNOA Comparison

Compare THAR & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THAR
  • SNOA
  • Stock Information
  • Founded
  • THAR 2017
  • SNOA 1999
  • Country
  • THAR United States
  • SNOA United States
  • Employees
  • THAR N/A
  • SNOA N/A
  • Industry
  • THAR Biotechnology: Pharmaceutical Preparations
  • SNOA Biotechnology: Pharmaceutical Preparations
  • Sector
  • THAR Health Care
  • SNOA Health Care
  • Exchange
  • THAR Nasdaq
  • SNOA Nasdaq
  • Market Cap
  • THAR 4.0M
  • SNOA 3.7M
  • IPO Year
  • THAR 2022
  • SNOA 2007
  • Fundamental
  • Price
  • THAR $2.03
  • SNOA $2.65
  • Analyst Decision
  • THAR Strong Buy
  • SNOA
  • Analyst Count
  • THAR 1
  • SNOA 0
  • Target Price
  • THAR $17.00
  • SNOA N/A
  • AVG Volume (30 Days)
  • THAR 47.8K
  • SNOA 44.7K
  • Earning Date
  • THAR 11-07-2024
  • SNOA 02-06-2025
  • Dividend Yield
  • THAR N/A
  • SNOA N/A
  • EPS Growth
  • THAR N/A
  • SNOA N/A
  • EPS
  • THAR N/A
  • SNOA N/A
  • Revenue
  • THAR N/A
  • SNOA $13,547,000.00
  • Revenue This Year
  • THAR N/A
  • SNOA $23.89
  • Revenue Next Year
  • THAR N/A
  • SNOA $25.45
  • P/E Ratio
  • THAR N/A
  • SNOA N/A
  • Revenue Growth
  • THAR N/A
  • SNOA 11.81
  • 52 Week Low
  • THAR $1.84
  • SNOA $2.44
  • 52 Week High
  • THAR $7.71
  • SNOA $9.40
  • Technical
  • Relative Strength Index (RSI)
  • THAR 45.25
  • SNOA 47.13
  • Support Level
  • THAR $1.86
  • SNOA $2.52
  • Resistance Level
  • THAR $2.06
  • SNOA $2.80
  • Average True Range (ATR)
  • THAR 0.11
  • SNOA 0.13
  • MACD
  • THAR -0.00
  • SNOA 0.00
  • Stochastic Oscillator
  • THAR 38.64
  • SNOA 39.39

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: